Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiprelestat in Pulmonary Arterial Hypertension (PAH)
NCT07601295Phase 2Not yet recruiting
- Sponsor
- Stanford University
- Start
- Jul 2026
- Primary completion
- Feb 2030
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of tiprelestat in pulmonary arterial hypertension (PAH), sponsored by Stanford University. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
tiprelestat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07601295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07601295.